CR8264A - Derivados de malonamida bloqueadores de la actividad gamma-secretase - Google Patents

Derivados de malonamida bloqueadores de la actividad gamma-secretase

Info

Publication number
CR8264A
CR8264A CR8264A CR8264A CR8264A CR 8264 A CR8264 A CR 8264A CR 8264 A CR8264 A CR 8264A CR 8264 A CR8264 A CR 8264A CR 8264 A CR8264 A CR 8264A
Authority
CR
Costa Rica
Prior art keywords
lower alkyl
blockers
gamma
halogen
secretase activity
Prior art date
Application number
CR8264A
Other languages
English (en)
Inventor
Flohr Alexander
Galley Guido
Jacob-Roetne Roland
A Kitas Eric
Peters Jens-Uwe
Wostl Wolfang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR8264A publication Critical patent/CR8264A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02Seven-membered rings
    • C07D313/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14[b,f]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invencion se refire a derivados de malonamida de la formula I en la que R1 es uno de los grupos siguientes a), b), c), d) R2 es alquilo inferior, alquinilo inferior, -(CH2) n- O -alquilo inferior, -(CH2) n-S-alquilo inferior, -(CH2) n -CN, -(CR'R") n -CF3, -(CR'R") n -CHF2, -(CR'R") n-CH2F,-(CH2)n-C (O) O-alquilo inferior, (CH2) n- halogeno, o es - (CH2) n- cicloalquilo, opcionalmente sustituido por uno o varios sustituyentes elegidos entre el grupo formado por fenilo, halogeno y CF3; R',R" con independencia de n y con independencia entre si son hidrogeno, alquilo inferior, alcoxi inferior, halogeno o hidroxi; R3, R4 con independencia entre si son hidrogeno, alquilo inferior, alcoxi inferior, fenilo o halogeno; R5 es hidrogeno, alquilo inferior, -(CH2) n -CF3 o - (CH2) n- cicloalquilo.
CR8264A 2003-09-09 2006-03-01 Derivados de malonamida bloqueadores de la actividad gamma-secretase CR8264A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03019683 2003-09-09

Publications (1)

Publication Number Publication Date
CR8264A true CR8264A (es) 2008-09-22

Family

ID=34224068

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8264A CR8264A (es) 2003-09-09 2006-03-01 Derivados de malonamida bloqueadores de la actividad gamma-secretase

Country Status (35)

Country Link
US (1) US7160875B2 (es)
EP (1) EP1711470B1 (es)
JP (2) JP4571639B2 (es)
KR (3) KR20070087233A (es)
CN (1) CN100593539C (es)
AR (1) AR045609A1 (es)
AT (1) ATE428698T1 (es)
AU (1) AU2004270361B2 (es)
BR (1) BRPI0413533A (es)
CA (1) CA2537440C (es)
CO (1) CO5660268A2 (es)
CR (1) CR8264A (es)
CY (1) CY1109225T1 (es)
DE (1) DE602004020680D1 (es)
DK (1) DK1711470T3 (es)
EA (1) EA009940B1 (es)
EC (1) ECSP066414A (es)
ES (1) ES2322652T3 (es)
HK (1) HK1099014A1 (es)
HR (1) HRP20090266T1 (es)
IL (1) IL173905A (es)
MA (1) MA28034A1 (es)
MX (1) MXPA06002562A (es)
MY (1) MY141308A (es)
NO (1) NO20061047L (es)
NZ (1) NZ545538A (es)
PL (1) PL1711470T3 (es)
PT (1) PT1711470E (es)
RS (1) RS20060146A (es)
SI (1) SI1711470T1 (es)
TN (1) TNSN06077A1 (es)
TW (1) TW200519092A (es)
UA (1) UA83501C2 (es)
WO (1) WO2005023772A1 (es)
ZA (1) ZA200601989B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069826A1 (en) * 2003-02-04 2004-08-19 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
DK1711470T3 (da) * 2003-09-09 2009-06-08 Hoffmann La Roche Malonamidderivater der blokerer aktiviteten af gamma-sekretase
AU2004283803B2 (en) * 2003-10-06 2010-06-24 F. Hoffmann-La Roche Ag Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors
US7211573B2 (en) 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
ES2398531T3 (es) * 2006-03-27 2013-03-20 F. Hoffmann-La Roche Ag Derivados de malonamida como inhibidores de gamma secretasa
BRPI0717587A2 (pt) * 2006-09-20 2013-10-29 Hoffmann La Roche Derivados de 4-oxo-2,3,4,5-tetra-hidro-benzo[b][1,4]diazepina
MX2009007864A (es) * 2007-02-02 2009-07-31 Hoffmann La Roche Derivados de 6-oxo-6,7-dihidro-5h-dibenzo[b,d]azepin-7-ilo.
EP2121579B1 (en) * 2007-03-15 2011-04-20 F. Hoffmann-La Roche AG Malonamides as orexin antagonists
US7579464B2 (en) * 2007-05-25 2009-08-25 Hoffmann-La Roche Inc. Process for preparation of enantiomerically pure compounds
US8741889B2 (en) 2008-01-11 2014-06-03 Hoffmann-La Roche Inc Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor
MA33076B1 (fr) * 2008-01-11 2012-03-01 Hoffmann La Roche Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
US8309299B2 (en) 2010-05-19 2012-11-13 Hoffmann-La Roche Inc. Combination therapy and method for assessing resistance to treatment
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
KR101330184B1 (ko) 2010-10-15 2013-11-15 성균관대학교산학협력단 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
WO2012050370A2 (ko) * 2010-10-15 2012-04-19 성균관대학교산학협력단 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
US20120114638A1 (en) 2010-11-08 2012-05-10 John Boylan Combination therapy
US20120184529A1 (en) 2011-01-14 2012-07-19 Demario Mark D Combination therapy
US20120225860A1 (en) 2011-03-02 2012-09-06 John Frederick Boylan Method for administration of a gamma secretase inhibitor
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯二氮呯酮化合物
JO3148B1 (ar) 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
EP2897947B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥
WO2014047390A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
US9133126B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzoazepinone compounds
EP2897946B1 (en) 2012-09-21 2016-11-16 Bristol-Myers Squibb Company N-substituted bis(fluoroalkkyl)-1,4-benzodiazepinone compounds as notch inhibitors
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
CN104822665A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物
WO2014165718A1 (en) 2013-04-04 2014-10-09 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
EP2932966A1 (en) 2014-04-16 2015-10-21 Novartis AG Gamma secretase inhibitors for treating respiratory diseases
KR102130458B1 (ko) * 2015-10-30 2020-07-08 파이프라인 테라퓨틱스, 아이엔씨. 디벤조 아제핀 화합물 및 귀 질환과 귀 장애 치료에서의 그의 용도
AU2017376109A1 (en) 2016-12-16 2019-07-11 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3668844A1 (en) * 2017-08-15 2020-06-24 Bayer Aktiengesellschaft 4-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepine-7-carboxamides
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
US20220332821A1 (en) 2019-06-24 2022-10-20 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CA3229806A1 (en) * 2021-08-31 2023-03-09 Basf Se Herbicidal malonamides containing a condensed ring system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404273A1 (en) * 2000-04-11 2001-10-18 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of a.beta. protein production
GB0012671D0 (en) * 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
WO2004069826A1 (en) * 2003-02-04 2004-08-19 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
DK1711470T3 (da) * 2003-09-09 2009-06-08 Hoffmann La Roche Malonamidderivater der blokerer aktiviteten af gamma-sekretase

Also Published As

Publication number Publication date
TW200519092A (en) 2005-06-16
PT1711470E (pt) 2009-05-21
DE602004020680D1 (de) 2009-05-28
EP1711470B1 (en) 2009-04-15
KR20070087233A (ko) 2007-08-27
JP2007505063A (ja) 2007-03-08
MA28034A1 (fr) 2006-07-03
AU2004270361B2 (en) 2009-06-25
IL173905A0 (en) 2006-07-05
CN1875005A (zh) 2006-12-06
ES2322652T3 (es) 2009-06-24
US20050054633A1 (en) 2005-03-10
ZA200601989B (en) 2007-05-30
NZ545538A (en) 2008-12-24
CA2537440A1 (en) 2005-03-17
SI1711470T1 (sl) 2009-08-31
RS20060146A (en) 2008-06-05
CN100593539C (zh) 2010-03-10
DK1711470T3 (da) 2009-06-08
KR100838852B1 (ko) 2008-06-16
BRPI0413533A (pt) 2006-10-10
ATE428698T1 (de) 2009-05-15
ECSP066414A (es) 2006-09-18
PL1711470T3 (pl) 2009-09-30
EP1711470A1 (en) 2006-10-18
MY141308A (en) 2010-04-16
AR045609A1 (es) 2005-11-02
UA83501C2 (uk) 2008-07-25
JP4571639B2 (ja) 2010-10-27
NO20061047L (no) 2006-04-04
EA200600503A1 (ru) 2006-08-25
CO5660268A2 (es) 2006-07-31
IL173905A (en) 2011-05-31
HRP20090266T1 (en) 2009-06-30
WO2005023772A1 (en) 2005-03-17
HK1099014A1 (en) 2007-08-03
TNSN06077A1 (fr) 2007-10-03
MXPA06002562A (es) 2006-06-20
KR20070087690A (ko) 2007-08-28
KR20060054455A (ko) 2006-05-22
EA009940B1 (ru) 2008-04-28
JP2010229153A (ja) 2010-10-14
CA2537440C (en) 2012-07-10
KR100834177B1 (ko) 2008-05-30
US7160875B2 (en) 2007-01-09
AU2004270361A1 (en) 2005-03-17
CY1109225T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
CR8264A (es) Derivados de malonamida bloqueadores de la actividad gamma-secretase
AR049784A1 (es) Derivados sustituidos de morfolina y tiomorfolina
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
NO20065830L (no) Substituerte 2-kinolyloksazoler som er anvendbare som PDE4-inhibitorer.
NO20071873L (no) DNA-PK inhibotorer.
DE60230266D1 (de) Phenylpyridincarbonyl piperazinderivate
HRP20070510T3 (en) Benzimidazole derivative and its use as a ii receptor antagonist
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
CO5040153A1 (es) Nuevos indenonaftopiranos fusionados heterociclicos fotocro- micos
TW200744994A (en) Insecticidal 3-acylaminobenzanilides
TW200634017A (en) Bi-and tricyclic substituted phenyl methanones
TNSN07255A1 (en) Cyclohexylamides as dopamine d3, d2 and 5ht 1a antagonists
DE602004028907D1 (de) Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
ATE526321T1 (de) Neue epoxidverbindung, alkalisch entwickelbare harzzusammensetzung und alkalisch entwickelbare lichtempfindliche harzzusammensetzung
CO6150147A2 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
CO6180439A2 (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos
MX2010004893A (es) Compuesto heterociclico y composicion farmaceutica del mismo.
RS52900B (en) Benzoylpyrazole Compound, Process for Production and Production of Herbicides Containing Them
AR044400A1 (es) Procesos para la preparacion de derivados de pirimidina
RS51389B (en) BENZIMIDAZOLE COMPOUNDS
AR060379A1 (es) Compuesto y composicion herbicida
AR039119A1 (es) Derivados de fenil amidas siliconadas utiles como microbiocidas
GEP20125660B (en) Improved organic compounds
ATE446948T1 (de) Alpha-ketoamidderivativ, herstellungsverfahren und verwendung davon
AR054414A1 (es) Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas.

Legal Events

Date Code Title Description
FC Refusal